SCHEMBL23576915

SCHEMBL23576915

C=Cc1cc2c(cc1F)c(N(C)c1cccc(F)c1)nc1nncn12

nearest known ligand 0.42

Predicted protein targets (top 5)

geneUniProtsupporting neighboursconfidence
▸ ABCG2 Q9UNQ0 1/20 0.40
▸ MAPT P10636 2/20 0.33
▸ PER2 O15055 1/20 0.31
▸ HCRTR1 O43613 1/20 0.30
▸ DHODH Q02127 1/20 0.30

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL29909020 1.00 ABCG2 (0.40) ABCG2MAPTPER2HCRTR1DHODH
SCHEMBL23601740 0.89 ABCG2 (0.40) ABCG2MAPTHCRTR1
SCHEMBL29909136 0.89 ABCG2 (0.40) ABCG2MAPTHCRTR1
SCHEMBL29909063 0.88 ABCG2 (0.46) ABCG2MAPTPER2HCRTR1DHODH
SCHEMBL23601280 0.88 ABCG2 (0.46) ABCG2MAPTPER2HCRTR1DHODH
SCHEMBL23601840 0.85 ABCG2 (0.41) ABCG2MAPTPER2HCRTR1
SCHEMBL23576978 0.85 ABCG2 (0.42) ABCG2MAPTPER2HCRTR1
SCHEMBL23576699 0.85 ABCG2 (0.42) ABCG2MAPTHCRTR1
SCHEMBL23577999 0.85 ABCG2 (0.42) ABCG2MAPTHCRTR1
SCHEMBL29909219 0.85 ABCG2 (0.42) ABCG2MAPTHCRTR1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 11 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20250361236-A9 DIACYLGLYCEROL KINASE MODULATING COMPOUNDS GILEAD SCIENCES INC (US) 2025-11-27 — — US disclosed
US-20240400568-A1 DIACYLGLYCEROL KINASE MODULATING COMPOUNDS GILEAD SCIENCES, INC. 2024-12-05 — — US disclosed
EP-4445902-A2 DIACYLGLYCEROL KINASE MODULATING COMPOUNDS Carna Biosciences, Inc. (JP) 2024-10-16 — — EP disclosed
EP-4081305-B1 DIACYLGLYCEROL KINASE MODULATING COMPOUNDS CARNA BIOSCIENCES INC (JP) 2024-09-18 — — EP disclosed
US-12054490-B2 Diacylglycerol kinase modulating compounds GILEAD SCIENCES, INC. (US) 2024-08-06 — — US disclosed
US-20240182476-A1 DIACYLGLYCEROL KINASE MODULATING COMPOUNDS GILEAD SCIENCES, INC. 2024-06-06 — — US disclosed
US-11845723-B2 Diacylglycerol kinase modulating compounds GILEAD SCIENCES, INC. (US) 2023-12-19 — — US disclosed
US-20220324866-A1 DIACYLGLYCEROL KINASE MODULATING COMPOUNDS GILEAD SCIENCES, INC. 2022-10-13 — — US disclosed
US-20220324866-A1 DIACYLGLYCEROL KINASE MODULATING COMPOUNDS GILEAD SCIENCES, INC. 2022-10-13 — — US disclosed
WO-2021130638-A1 DIACYLGLYCEROL KINASE MODULATING COMPOUNDS CARNA BIOSCIENCES, INC. (JP) 2021-07-01 — — WO disclosed
WO-2021130638-A1 DIACYLGLYCEROL KINASE MODULATING COMPOUNDS CARNA BIOSCIENCES, INC. (JP) 2021-07-01 — — WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20240400568-A1 DIACYLGLYCEROL KINASE MODULATING COMPOUNDS DGKG, DGKB, DGKK ABCG2 4216/4885MAPT 4206/4885PER2 3692/4885
US-20220324866-A1 DIACYLGLYCEROL KINASE MODULATING COMPOUNDS DGKG, DGKB, DGKK ABCG2 4216/4885MAPT 4206/4885PER2 3692/4885
US-12054490-B2 Diacylglycerol kinase modulating compounds DGKG, DGKB, DGKK ABCG2 4216/4885MAPT 4206/4885PER2 3692/4885
US-11845723-B2 Diacylglycerol kinase modulating compounds DGKG, DGKB, DGKK ABCG2 4216/4885MAPT 4206/4885PER2 3692/4885
US-20240182476-A1 DIACYLGLYCEROL KINASE MODULATING COMPOUNDS DGKG, DGKB, DGKK ABCG2 4216/4885MAPT 4206/4885PER2 3692/4885
US-20250361236-A9 DIACYLGLYCEROL KINASE MODULATING COMPOUNDS DGKG, DGKB, DGKK ABCG2 4216/4885MAPT 4206/4885PER2 3692/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.

Send feedback